Lv4
490 积分 2021-05-13 加入
Neoadjuvant immunotherapy plus chemotherapy in high altitude natives with resectable esophageal squamous cell carcinoma in Tibet
2天前
已完结
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)
2天前
已完结
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
1个月前
已完结
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
1个月前
已完结
Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial
1个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
2个月前
已完结
Safer approaches to therapeutic modulation of TGF-β signaling for respiratory disease
2个月前
已完结
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease
2个月前
已完结
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
2个月前
已完结
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)
3个月前
已完结
皖公网安备34019202002308
